What Is TB-500? Research Evidence & Profile

What Is Thymosin Beta-4 (TB-500)?

Thymosin Beta-4 (TB-500) is a peptide entry identified by the Thymosin Beta-4 and TB-500 names. This page identifies the material as TB-500 (Thymosin Beta-4 17-23 Fragment), with amino acid count 7; synonyms TB-500; Thymosin Beta-4 17-23 fragment. The Thymosin Beta-4 (TB-500) identifiers distinguish this catalogue entry from similarly named compounds, fragments, modified analogues, and multi-component formulations.

Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation.

Evidence at a Glance

1ClinicalTrials.gov query records

28PubMed query records

6Selected publications shown

Sources: ClinicalTrials.gov query · PubMed query · Retrieved 2026-10-06

Mechanism & Pharmacology

The research record for Thymosin Beta-4 (TB-500) is organized around thymosin peptide characterization, actin-related research literature, signal-pathway studies, and analytical peptide workflows. For Thymosin Beta-4 (TB-500), those subjects define the literature and analytical context of this specific research peptide; they do not establish a clinical indication, administration route, or expected outcome.

Mechanistic or pathway language defines a research scope. It does not establish that a catalogue product produces a clinical effect.

Clinical Development

Selected exact-query registry records are shown below. Desktop displays up to six; mobile displays up to three.

NCT ID / Study	Phase	Status	Context	Last registry update
NCT07487363TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD	Phase 1/Phase 2	Recruiting	Atherosclerotic Cardiovascular Diseases, Endothelial Dysfunction	2026-03-23

Source: ClinicalTrials.gov search · Retrieved 2026-10-06

Selected Literature6 important records shown

Selected Literature

Selected PubMed record

Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.

The American journal of sports medicine · 2026 Jan

PMID 41476424

Selected PubMed record

Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.

Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews · 2026 Jan 1

PMID 41490200

Selected PubMed record

Peptide Supplements and Their Therapeutic Applications in Sports Medicine.

The American journal of sports medicine · 2026 Aug 11

PMID 42578445

Selected PubMed record

Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.

Sports medicine (Auckland, N.Z.) · 2026 Aug

PMID 41966639

Selected PubMed record

Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences · 2024 Mar 1

PMID 38382158

Selected PubMed record

Therapeutic peptides in gerontology: mechanisms and applications for healthy aging.

Frontiers in aging · 2026

PMID 42021992

Source: PubMed search results · Retrieved 2026-10-06

Identity & ChemistryProduct-form fields

Identity & Chemistry

Compound / Blend: TB-500 (Thymosin Beta-4 17-23 Fragment)
Available Specifications: 2mg, 5mg, 10mg
Pack Format: 10 Vials
CAS Number: 885340-08-9
Molecular Formula: C38H68N10O14
Molecular Weight: 889.02 g/mol
Amino Acid Count: 7
Sequence: Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln-OH (Thymosin β4 17-23 active fragment)
Synonyms: TB-500; Thymosin Beta-4 17-23 fragment
Physical Form: Lyophilized powder

Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation.

Source: PubChem CID 62707662 · Product form must still be matched to the catalogue and batch record.

Research Tools for Thymosin Beta-4 (TB-500)

Review the selected registry records and open the module-level ClinicalTrials.gov query for the current result set.

Open Clinical Development

Use the complete NOVABIO documentation library to review currently available batch records.

Open Lab Results & COA

Storage & Laboratory HandlingDocumentation-led controls

Storage & Laboratory Handling

Confirm the exact material form, lot, supplied state and storage statement from the product label and corresponding batch documentation. Do not infer handling conditions from a different compound, strength or external clinical publication.

Regulatory Status

FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval.

Source: FDA Drugs@FDA · Checked 2026-10-06

Authoritative Data Summary

Thymosin Beta-4 (TB-500) Research Summary

Identity

TB-500 (Thymosin Beta-4 17-23 Fragment); specifications: 2mg, 5mg, 10mg. Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation.

Mechanism

Evidence

1 registry records and 28 PubMed records were returned by the displayed query on 2026-10-06; counts are not quality ratings.

Regulatory context

FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval.

Thymosin Beta-4 (TB-500) is represented here by the catalogue identity TB-500 (Thymosin Beta-4 17-23 Fragment). Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation. The product record lists 2mg, 5mg, 10mg as the currently available specifications. The research context is organized around this product-specific scope: The research record for Thymosin Beta-4 (TB-500) is organized around thymosin peptide characterization, actin-related research literature, signal-pathway studies, and analytical peptide workflows. For Thymosin Beta-4 (TB-500), those subjects define the literature and analytical context of this specific research peptide; they do not establish a clinical indication, administration route, or expected outcome. The synchronized searches returned 1 ClinicalTrials.gov records and 28 PubMed records for the displayed query. A registry count includes records with different designs, statuses and populations, while a publication count can include reviews, preclinical work and unrelated uses of a shared abbreviation; neither count is a quality score. For regulatory interpretation, FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval. Clinical findings apply only to the studied drug product, formulation, population and protocol. NOVABIO product specifications and batch documentation are separate catalogue records and do not inherit clinical outcomes from external studies. This profile supports identity checking, source tracing and laboratory record review; it does not certify a batch, recommend treatment, provide dosing instructions or replace current official labeling and professional judgment.

Sources: PubMed · ClinicalTrials.gov · FDA · NOVABIO product record

FAQ4 evidence-bounded answers

Thymosin Beta-4 (TB-500) FAQ

What is Thymosin Beta-4 (TB-500)?

What research records are indexed for Thymosin Beta-4 (TB-500)?

The synchronized query returned 1 ClinicalTrials.gov records and 28 PubMed records on 2026-10-06; review the linked searches because counts and record status can change.

Is Thymosin Beta-4 (TB-500) FDA approved?

FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval.

Does this page provide dosing guidance?

No. This research profile provides identity, evidence, chemistry, regulatory and documentation context without dosing or treatment instructions.

Sources, Methodology & Last Verified

Official sources: ClinicalTrials.gov, NCBI PubMed, FDA, available PubChem records, and NOVABIO product and COA records.
Query retrieved: 2026-10-06T12:08:49Z
Inclusion: Exact identity terms and traceable registry, publication, chemistry, regulatory or catalogue fields.
Limitations: Search counts can include mixed evidence types and shared-name records; individual records require direct review.
Prepared by: NOVABIO Research
Reviewed date: 2026-10-06
Editorial methodology: How NOVABIO builds Research Profiles
Corrections contact: Contact NOVABIO with the page URL and source record.